AMAM
Income statement / Annual
Last year (2022), Ambrx Biopharma Inc.'s total revenue was $7.40 M,
a decrease of 0.71% from the previous year.
In 2022, Ambrx Biopharma Inc.'s net income was -$78.00 M.
See Ambrx Biopharma Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$7.40 M
|
$7.46 M
|
$13.67 M
|
$10.31 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$7.40 M |
$7.46 M |
$13.67 M |
$10.31 M |
| Gross Profit Ratio |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$53.31 M
|
$54.81 M
|
$20.43 M
|
$26.38 M
|
| General & Administrative
Expenses |
$20.33 M
|
$17.07 M
|
$6.35 M
|
$6.40 M
|
| Selling & Marketing
Expenses |
$2.73 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$23.05 M
|
$17.07 M
|
$6.35 M
|
$6.40 M
|
| Other Expenses |
-$2.22 M |
-$3.86 M |
-$4.75 M |
-$38,000.00 |
| Operating Expenses |
$74.14 M |
$71.88 M |
$26.79 M |
$32.78 M |
| Cost And Expenses |
-$83.83 M |
$71.88 M |
$26.79 M |
$32.78 M |
| Interest Income |
$369,000.00 |
$0.00 |
$27,000.00 |
$195,000.00 |
| Interest Expense |
$968,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.29 M
|
$2.15 M
|
$1.94 M
|
$2.05 M
|
| EBITDA |
-$55.79 M
|
-$62.27 M
|
-$11.17 M
|
-$20.42 M
|
| EBITDA Ratio |
-7.54 |
-8.35 |
-0.82 |
-1.98 |
| Operating Income Ratio
|
-7.71
|
-8.64
|
-0.96
|
-2.18
|
| Total Other
Income/Expenses Net |
-$18.98 M
|
-$3.86 M
|
-$4.72 M
|
$157,000.00
|
| Income Before Tax |
-$76.06 M |
-$68.29 M |
-$17.84 M |
-$22.32 M |
| Income Before Tax Ratio
|
-10.28
|
-9.16
|
-1.3
|
-2.16
|
| Income Tax Expense |
$1.94 M |
$1,000.00 |
$1,000.00 |
-$2,000.00 |
| Net Income |
-$78.00 M |
-$68.29 M |
-$17.84 M |
-$22.31 M |
| Net Income Ratio |
-10.54 |
-9.16 |
-1.3 |
-2.16 |
| EPS |
-2.02 |
-3.34 |
-0.47 |
-0.59 |
| EPS Diluted |
-2.02 |
-3.34 |
-0.47 |
-0.59 |
| Weighted Average Shares
Out |
$38.61 M
|
$20.45 M
|
$37.67 M
|
$37.67 M
|
| Weighted Average Shares
Out Diluted |
$38.61 M
|
$20.45 M
|
$37.67 M
|
$37.67 M
|
| Link |
|
|
|
|
